601 / 1631
Lenalidomide + Obinituzimab: Results
•
Median # of prior therapies: 2
•
Lenalidomide + obinutuzumab was
well tolerated with 100% ORR and
no unexpected toxicity.
94
Overall Response: 100%
•
Grade 3+ neutropenia: 27%
Adverse Events
Progression Free Survival
Fowler N, et al. ASCO 2017
24mo. PFS: 61% (95% CI: .43-.87)
Also see: Morchhauser F. et al. ICML. Wed. June 14th